Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. This series is based on primary research data collected at one month, six months, and one year post-commercial availability of Nucala. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The analysis also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologic therapies. This module also includes an overview and pipeline analysis of emerging asthma therapies from early to late phase clinical development as well as detailed profiles, expert insights, and commercial outlook for select therapies in late-phase commercial development.